Dec 20, 2017 8:45 am EST Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
Nov 15, 2017 8:25 am EST Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
Nov 9, 2017 8:45 am EST Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
Oct 19, 2017 9:39 am EDT Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Oct 16, 2017 8:27 am EDT Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies
Oct 11, 2017 8:19 am EDT Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
Oct 6, 2017 8:25 am EDT Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa
Oct 4, 2017 8:45 am EDT Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio
